GlassScriptPhysician profile
Michael M Samiratedu
NPI 1750801288
$2,821.52
in general payments reported to CMS, 2019-2025
21 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2021: $247 · 2022: $159 · 2023: $398 · 2024: $581 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $388.39 | 2022-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $316.93 | 2021-2024 | Farxiga, Evusheld |
| Calliditas Therapeutics US INC. | $303.62 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $284.53 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $265.25 | 2024-2025 | |
| Medtronic, INC. | $165.43 | 2025 | Symplicity G3 |
| Otsuka America Pharmaceutical, INC. | $163.48 | 2022-2025 | Jynarque |
| Travere Therapeutics, INC. | $152.99 | 2022-2025 | |
| Glaxosmithkline, LLC. | $134.84 | 2019-2023 | Benlysta |
| Novo Nordisk INC | $113.94 | 2024-2025 | Rivfloza, Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $106.38 | 2022-2024 | Lupkynis |
| Ardelyx, INC. | $105.41 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $89.39 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $59.03 | 2022-2025 | Velphoro |
| Kyowa Kirin, INC. | $28.38 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $28.24 | 2025 | |
| Ani Pharmaceuticals, INC. | $27.37 | 2022 | |
| Apellis Pharmaceuticals, INC. | $24.66 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.05 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.84 | 2023 | |
| Amgen INC. | $18.37 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Samiratedu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.